Skip to main content

Advertisement

SpringerLink
Log in

Anti-TNF-α antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To compare the effect of oral glucocorticoid (GC) therapy with the effect of intravenous anti-TNF-α-therapy on serum VEGF levels of patients with rheumatoid arthritis (RA). Five RA patients (5/8) who had no prior treatment with DMARDs (Disease modifying antirheumatic drugs) or GCs were administered 20 mg prednisolone daily. Three patients who failed more than one DMARD therapy received infusion with Infliximab (200 mg). VEGF-serum levels were measured by enzyme-linked immunosorbent assay before treatment,and at day 10 or 13 during prednisolone therapy, or 14 days after the first Infliximab infusion. Serum VEGF levels in therapy naive RA patients (GC group) were higher than those in pretreated patients who received Infliximab (median serum VEGF level: 1106 vs 320 pg/ml; P=0.1). Treatment with Infliximab as well as GCs significantly decreased serum VEGF levels after 10–14 days in RA patients (median serum VEGF level after treatment: GC group 559 pg/ml, Infliximab group 92 pg/ml; P=0.01 vs without treatment or preinfusion). Conclusions: Anti-TNF-α antibody Infliximab as well as GC are able to decrease serum VEGF levels in patients with active RA. Whether therapeutic reduction of serum VEGF levels is associated with inhibition of angiogenesis should be evaluated in future by imaging of synovial vasculature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Schrieber L, Jackson JC (2004) Angiogenesis in Rheumatoid Arthritis. In: Klippel HJ, Dieppe PA (eds) Rheumatology, 2nd edn, vol 1. Mosby International, London, England, pp 12.1–12.4

    Google Scholar 

  2. Koch AE (1998) Angiogenesis—implications for rheumatoid arthritis. Arthritis Rheum 41(6):951–962

    CAS  PubMed  Google Scholar 

  3. Jain A, Nanchahal J, Troeberg L, Green P, Brennan F (2001) Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum 44(8):1754–1760

    CAS  PubMed  Google Scholar 

  4. Koch AE, Volin MV, Woods JM, Kunkel SL, Connors MA, Harlow LA, Woodruff DC, Burdick MD, Strieter RM (2001) Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 44(1):31–40

    CAS  PubMed  Google Scholar 

  5. Paleolog EM (1996) Angiogenesis: a critical process in the pathogenesis of RA—a role of VEGF?. Br J Rheumatol 35:917–919

    CAS  PubMed  Google Scholar 

  6. Afuwape AO, Kiriakidis S, Paleolog EM (2002) The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol 17(3):961–972

    CAS  PubMed  Google Scholar 

  7. Nagashima M, Yoshino S, Ishiwata T, Asano G (1995) Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 22:1624–1630

    CAS  PubMed  Google Scholar 

  8. Kasama T, Shiozawa F, Kobayashi K, Yajima N, Hanyuda M, Takeuchi HT, Mori Y, Negishi M, Ide H, Adachi M (2001) Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis. Arthritis Rheum 44(11):2512–2524

    CAS  PubMed  Google Scholar 

  9. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 27:377–380

    CAS  PubMed  Google Scholar 

  10. Wauke K, Nagashima M, Ishiwata T, Asano G, Yoshino S (2002) Expression and localization of vascular endothelial growth factor-C in rheumatoid arthritis synovial tissue. J Rheumatol 29(1):34–38

    CAS  PubMed  Google Scholar 

  11. Latour F, Zabraniecki L, Dromer C, Brouchet A, Durroux R, Fournie B (2001) Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological and pathological study in 12 patients monitored for 10 years. Joint Bone Spine 68(6):493–498

    CAS  PubMed  Google Scholar 

  12. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM (2001) Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44(9):2055–2064

    CAS  PubMed  Google Scholar 

  13. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini R (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41(7):1258–1265

    CAS  PubMed  Google Scholar 

  14. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48(6):1521–1529

    CAS  PubMed  Google Scholar 

  15. Ha IS, Um EY, Jung HR, Park HW, Cheong HI, Choi Y (2002) Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 39(5):1001–1010

    CAS  PubMed  Google Scholar 

  16. Pinheiro GR, Andrade CA, Gayer CR, Coelho MS, Freire SM, Scheinberg MA (2001) Serum vascular endothelial growth factor in late rheumatoid arthritis. Clin Exp Rheumatol 19(6):721–723

    CAS  PubMed  Google Scholar 

  17. Kompella UB, Bandi N, Ayalasomayajula SP (2003) Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophtalmol Vis Sci 44(3):1192–1201

    Google Scholar 

  18. Edelman JL, Castro MR, Wen Y (1999) Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophtalmol Vis Sci 40(6):1112–1123

    CAS  Google Scholar 

  19. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M (1998) Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341(2–3):309–315

    CAS  PubMed  Google Scholar 

  20. Bandi N, Kompella UB (2001) Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol 425(2):109–116

    CAS  PubMed  Google Scholar 

  21. Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C, Silvestri T, Frizziero L (2000) Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum 43(11):2472–2480

    CAS  PubMed  Google Scholar 

  22. Nagashima M, Wauke K, Hirano D, Ishigami S, Aono H, Takai M, Sasano M, Yoshino S (2000) Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology 39:1255–1262

    CAS  PubMed  Google Scholar 

  23. Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim HY (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19(3):321–324

    CAS  PubMed  Google Scholar 

  24. Strunk J, Lange U, Kürten B, Schmidt KL, Neeck G (2003) Doppler sonographic findings in the long bicipital tendon sheath in patients with rheumatoid arthritis as compared with patients with degenerative diseases of the shoulder. Arthritis Rheum 48(7):1828–1832

    PubMed  Google Scholar 

  25. Terslev L, Torp-Pedersen S, Savnik A, von der Recke P, Qvistgaard E, Danneskiold-Samsoe B, Bliddal H (2003) Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis: a comparative study. Arthritis Rheum 48(9):243–241

    Google Scholar 

  26. Strunk J, Lange U (2004) Three-dimensional power Doppler sonographic visualization of synovial angiogenesis in rheumatoid arthritis. J Rheumatol 31(5):1004–1006

    PubMed  Google Scholar 

  27. Strunk J, Heinemann E, Schmidt KL, Neeck G, Lange U (2004) A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and serum vascular endothelial growth factor (VEGF) level measurement. Rheumatology 43:1480–1483

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Kerckhoff-Clinic and Foundation, University of Giessen, Benekestrasse 2-8, 61231, Bad Nauheim, Germany

    Johannes Strunk, Elisabeth Bundke & Uwe Lange

Authors
  1. Johannes Strunk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth Bundke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uwe Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Strunk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strunk, J., Bundke, E. & Lange, U. Anti-TNF-α antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int 26, 252–256 (2006). https://doi.org/10.1007/s00296-005-0619-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-005-0619-5

Keywords

Search

Navigation